The association between diabetes mellitus (and its micro- and macro-vascular complications) and erectile dysfunction is widely known and the presence of hypogonadism may further complicate sexual dysfunction and quality of life, given the association between hypogonadism and reduced libido, ejaculatory disorders, and depressive symptoms. However, the recent introduction of novel antidiabetic agents with a wide range of mechanism of action may have a significant impact both on male and female sexuality directly (by inducing side effects as urinary tract infections) and indirectly (improving metabolic status and reducing diabetes complications behind sexual dysfunctions). To date only few papers are reporting the sexual effects of these treatments and, often, these are not comparable in their results. Conversely, female sexual dysfunctions are somehow under-investigated. Data on prevalence is heterogeneous and specific pathogenic mechanisms, as well as the burden of psychological factors, are still heatedly debated. The aim of this narrative review is to summarize current knowledge and stressing out the need to diagnose male and female sexual dysfunctions also in light of the impact of treatments with novel antidiabetic agents. This would highlight the still unmet needs for sexual care in a diabetes care setting and could represent an incentive for future discussions, as well as a required theoretical starting point for studies on this subject.

Male and female sexual dysfunction in diabetic subjects: Focus on new antihyperglycemic drugs / Corona, G.; Isidori, A. M.; Aversa, A.; Bonomi, M.; Ferlin, A.; Foresta, C.; La Vignera, S.; Maggi, M.; Pivonello, R.; Vignozzi, L.; Lombardo, F.. - In: REVIEWS IN ENDOCRINE & METABOLIC DISORDERS. - ISSN 1389-9155. - 21:1(2020), pp. 57-65. [10.1007/s11154-019-09535-7]

Male and female sexual dysfunction in diabetic subjects: Focus on new antihyperglycemic drugs

Isidori A. M.;Aversa A.;Ferlin A.;Foresta C.;Pivonello R.;Vignozzi L.;Lombardo F.
2020

Abstract

The association between diabetes mellitus (and its micro- and macro-vascular complications) and erectile dysfunction is widely known and the presence of hypogonadism may further complicate sexual dysfunction and quality of life, given the association between hypogonadism and reduced libido, ejaculatory disorders, and depressive symptoms. However, the recent introduction of novel antidiabetic agents with a wide range of mechanism of action may have a significant impact both on male and female sexuality directly (by inducing side effects as urinary tract infections) and indirectly (improving metabolic status and reducing diabetes complications behind sexual dysfunctions). To date only few papers are reporting the sexual effects of these treatments and, often, these are not comparable in their results. Conversely, female sexual dysfunctions are somehow under-investigated. Data on prevalence is heterogeneous and specific pathogenic mechanisms, as well as the burden of psychological factors, are still heatedly debated. The aim of this narrative review is to summarize current knowledge and stressing out the need to diagnose male and female sexual dysfunctions also in light of the impact of treatments with novel antidiabetic agents. This would highlight the still unmet needs for sexual care in a diabetes care setting and could represent an incentive for future discussions, as well as a required theoretical starting point for studies on this subject.
2020
Antidiabetic agents; Diabetes mellitus; Erectile function; Female sexual dysfunctions; Sexual dysfunctions; Animals; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Erectile Dysfunction; Female; Humans; Hypoglycemic Agents; Hypogonadism; Libido; Male; Sexual Dysfunction, Physiological
01 Pubblicazione su rivista::01a Articolo in rivista
Male and female sexual dysfunction in diabetic subjects: Focus on new antihyperglycemic drugs / Corona, G.; Isidori, A. M.; Aversa, A.; Bonomi, M.; Ferlin, A.; Foresta, C.; La Vignera, S.; Maggi, M.; Pivonello, R.; Vignozzi, L.; Lombardo, F.. - In: REVIEWS IN ENDOCRINE & METABOLIC DISORDERS. - ISSN 1389-9155. - 21:1(2020), pp. 57-65. [10.1007/s11154-019-09535-7]
File allegati a questo prodotto
File Dimensione Formato  
10.1007@s11154-019-09535-7.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 431.83 kB
Formato Adobe PDF
431.83 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1557079
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 23
social impact